Vertex Pharmaceuticals Incorporated
Company Information

50 Northern Ave
Boston, MA, 02210 United States
(617) 341-6100

Vertex Pharmaceuticals Incorporated Rankings

S&P 500
#416 in FT Global 500 (June 2015)

Top 3 Competitors

Unlock more access to Hoover’s!

  • Build customized email lists 24/7, based on your best customer profile.
  • Learn more about the companies you want to sell to. Hoover’s has reports on 85+ million companies and 900 industries. 65,000 data points are updated each day.
  • Get real insight written by real people – exclusive research and reviews by our in-house Editorial staff.
  • We can deliver our data to your desktop, to Excel, direct to your CRM, into your custom app, or via mobile.

Call (866) 473-3932 today to get started with a FREE TRIAL!


Vertex Pharmaceuticals Incorporated Company Profile

Vertex Pharmaceuticals aims to cure patients with previously incurable diseases. The biotechnology firm uses an integrated, multidisciplinary approach -- employing biophysics, computer-based modeling, and functional genomics -- to speed up the discovery and development of new drugs. Its orphan drugs Kalydeco and Orkambi (launched in 2015) are used to treat cystic fibrosis; the firm is also seeking approval for the medications for other indications. Vertex has other drugs in development, including additional treatments for cystic fibrosis as well as cancer, pain, and the flu. The firm's first drug, the blockbuster hepatitis C treatment Incivek, was discontinued in 2014 after Gilead's popular Sovaldi hit the market.